NCT04128059View on ClinicalTrials.gov

Study of Safety and Immunogenicity of BVRS-GamVac-Combi

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

July 1, 2021

Study Completion Date

December 31, 2021

Conditions
MERS (Middle East Respiratory Syndrome)MERS
Interventions
DRUG

BVRS-GamVac-Combi

"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"

OTHER

placebo

placebo

Trial Locations (1)

Unknown

RECRUITING

ECO-Safety, Saint Petersburg

Sponsors
All Listed Sponsors
collaborator

Acellena Contract Drug Research and Development

OTHER

lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER